Mizuho analyst Ann Hynes raised the firm’s price target on Cardinal Health to $74 from $66 and keeps a Neutral rating on the shares post the Q3 results. The recovery in core business volumes remains a tailwind for the drug distributors, Hynes tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CAH: